12:00 AM
Jul 30, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Kruppel-like factor 4 (KLF4; EZF); galectin-3 (LGALS3)

Cardiovascular disease

INDICATION: Atherosclerosis

Cell culture and mouse studies suggest inhibiting KLF4 could help treat atherosclerosis. In atherosclerotic plaques, phenotypic conversion of smooth muscle cells to macrophage-like LGALS3-positive cells increases inflammation and reduces fibrous cap area, which promotes...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >